Objectives: There is evidence of monocyte/macrophage infiltration and increased interleukin (IL)-1 expression, along with increased extracellular matrix (ECM) and fibrosis in the myocardial interstitium, during the course of parasitic, viral and idiopathic myocarditis. The aim of this study was to determine the effect of human and rat IL-1 on the production of fibronectin (FN) by rat cardiac fibroblast cultures. Methods: To test the role of IL-1 in the production of ECM, we determined the FN content in supernatants of rat myocardial fibroblast cultures incubated for 72 h with different doses of human recombinant IL-1β or with supernatants from lipopolysaccharide (LPS)-stimulated rat macrophage cultures. The content of soluble FN was determined by ELISA. In addition, IL-1β transcription was also investigated in controls and human recombinant IL-1β-treated fibroblast cultures. Results: There was a significant, dose-dependent FN-stimulatory effect of recombinant human IL-1β and LPS-stimulated macrophage-conditioned medium when they were used to stimulate fibroblast cultures. The stimulatory effect on FN production was found to be diminished after treatment of macrophage supernatants with an antibody against rat IL-1. Increased transcription of IL-1β was found in human recombinant IL-1β-treated cardiac fibroblasts. Conclusion: Our data suggest that the FN-stimulatory effect of IL-1 on cardiac fibroblasts could be responsible, in part, for interstitial ECM accumulation during the course of myocarditis.

Keywords:
Fibronectin, Fibrosis, Cardiac fibroblast, Interleukin-1, Myocarditis
This content is only available via PDF.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.